{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026162","form_type":"8-K","ticker":"AMIX","cik":"0001617867","company_name":"Autonomix Medical, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.794683+00:00","generated_at":"2026-05-31T09:43:26.972486+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Autonomix Medical reports Q1 FY2025 net loss $2.7M, positive 7-day pain relief data from lead-in patients","bullets":["Net loss $2.7M vs $0.9M YoY; cash $6.8M as of June 30, 2024.","G&A $1.8M (up $1.3M) and R&D $1.0M (up $0.6M) driven by compensation and clinical costs.","60% of first five lead-in patients had mean 6.33 VAS pain reduction (from 8.0 to 1.67) at 7 days.","Appointed Brad Hauser CEO; licensed RF Innovations' FDA-cleared Apex 6 ablation generator.","Expects topline PoC trial data 1H CY2025, FDA de novo submission 2026, clearance 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026162","json":"https://secwatch.observer/filing/0001437749-24-026162.json","markdown":"https://secwatch.observer/filing/0001437749-24-026162.md","text":"https://secwatch.observer/filing/0001437749-24-026162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1617867/000143774924026162/0001437749-24-026162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1617867/000143774924026162/amix20240812_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:43:26.972486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}